EUCTR2013-005036-20-DK进行中（未招募）1 期
Recombinant Factor VIIa: Local treatment of severe postpartum hemorrhage - rFVIIa: Local treatment of PPH
Stellaris Pharmaceuticals ApS0 个研究点开始时间: 2014年2月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Patients with Placenta Previa
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with allergy to NovoSeven RT or to mice; guinea pig or bovine proteins.
- •Patients with coagulation disorders.
研究者
相似试验
进行中（未招募）
1 期
Recombinant Factor VIIa for acute bleeding in the brain (Hemorrhagic Stroke) administered at earliest Time - (FASTEST) TrialEUCTR2019-003722-25-GBniversity of Cincinnati860
已完成
3 期
The comparison of efficacy between Novoseven® and Recombinant factor VIIa (Aryogen)congenital FVII deficiency.Hereditary deficiency of other clotting factorsIRCT201104266302N1AryoGen Biopharma Company66
已完成
3 期
Efficacy analysis of Recombinant factor VIIa (Aryogen) in Comparison with Novoseven® on patients with congenital hemophilia A/B with inhibitorscongenital hemophilia A/B with inhibitors.Hereditary factor VIII deficiency, Hereditary factor IX deficiencyD66, D67IRCT201202106302N2AryoGen Biopharma Company66
已完成
不适用
Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains MalaysiaMassive HemorrhageMassive Blood LossMassive Blood Transfusion ThrombocytopeniaNCT03251547Universiti Sains Malaysia76
Unknown
不适用
A Single and Low Dose of Recombinant Factor VIIa in Patients With Severe Factor XI Deficiency Undergoing SurgeryHemophilia CNCT01538160Sheba Medical Center15